Financiado en parte por Nutrition Scientific Research Foundation of BYHEALTH
Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality
Jiang H, Wang L, Wang D, Yan N, Li C, Wu M, Wang F, Mi B, Chen F, Jia W, Liu X, Lv J, Liu Y, Lin J, Ma L
Clinical nutrition (Edinburgh, Scotland) · 76 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Nutrition Scientific Research Foundation of BYHEALTH
- Gobierno
- National Natural Science Foundation of China
- Gobierno
- Fundamental Research Funds for the Central Universities
- Gobierno
- Shanxi Provincial Key Research and Development Project
- Subvenciones
- National Natural Science Foundation of China (NSFC-82022062); Fundamental Research Funds for the Central Universities (xzy032019008); Fundamental Research Funds for the Central Universities (qngz2016004); National Natural Science Foundation of China (NSFC-81973025); Nutrition Scientific Research Foundation of BYHEALTH (TY0181101); Shanxi Provincial Key Research and Development Project (2022SF-185)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2022-06-30 · Clin Nutr · vol. 41 · número 8 · págs. 1798–1807
- Editorial
- Elsevier BV
- Citado
- 115 citas · más que el 99% de estudios similares · 11.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 120 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Nutritional Studies and Diet · Aquaculture Nutrition and Growth
- Palabras clave
- omega-3 polyunsaturated fatty acids, fatty acid biomarkers, type 2 diabetes, cardiovascular disease, coronary artery disease, stroke, colorectal cancer, cancer risk, mortality, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, docosapentaenoic acid, cardiometabolic disease
- MeSH
- humans, neoplasms, cardiovascular diseases, coronary disease, diabetes mellitus, type 2, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, fatty acids, unsaturated, prospective studies, biomarkers
15 autores
- Hong Jiang🇨🇳Xi'an Jiaotong University
- Lina Wang🇨🇳Xi'an Jiaotong University
- Duolao Wang🇬🇧Liverpool School of Tropical Medicine
- Ni Yan🇨🇳Xi'an Jiaotong University
- Chao Li🇨🇳Xi'an Jiaotong University
- Min Wu🇨🇳Xi'an Jiaotong University
- Fan Wang🇨🇳Xi'an Jiaotong University
- Baibing Mi🇨🇳Xi'an Jiaotong University
- Fangyao Chen🇨🇳Xi'an Jiaotong University
- Wanru Jia🇨🇳Xi'an Jiaotong University
- Xi Liu🇨🇳Xi'an Jiaotong University
- Jiaxin Lv🇨🇳Xi'an Jiaotong University
- Yan Liu🇨🇳Xi'an Jiaotong University
- Jing Lin🇨🇳 · autor de correspondenciaXi'an Jiaotong University
- Le Ma🇨🇳 · autor de correspondenciaXi'an Jiaotong University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background & aims
Considerable attention has focused on the role of omega-3 polyunsaturated fatty acids (PUFA) in the prevention of cardiometabolic diseases, which has led to dietary recommendations to increase omega-3 fatty acid intake. A meta-analysis was conducted to summarize evidence from prospective studies regarding associations between omega-3 PUFA biomarkers and risk of developing major chronic diseases.
Methods
Four electronic databases were searched for articles from inception to March 1, 2022. Random-effects model was used to estimate the pooled relative risk (RR) and 95% confidence intervals (CIs) for the association of omega-3 PUFAs, including α-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA), with risk of developing type 2 diabetes (T2D), cardiovascular disease (CVD), including coronary heart disease (CHD) and stroke, cancer, and mortality. The Grades of Recommendation, Assessment, Development and Evaluation assessment tool was used to rates the confidence in estimates.
Results
A total of 67 prospective studies comprised of 310,955 participants were identified. Individual omega-3 PUFAs showed divergent associations with the study outcomes of interest. A significant inverse association with T2D risk was observed across categories of ALA (relative risk [RR]: 0.89, 95% confidence interval [CI]: 0.82-0.96), EPA (RR: 0.85, 95% CI: 0.72-0.99) and DPA (RR: 0.84, 95% CI: 0.73-0.96) biomarkers. The marine-origin omega-3 fatty acids biomarkers but not ALA was significantly associated with lower risks of total CVD, CHD, and overall mortality, with RRs ranging from 0.70 for DHA-CHD association to 0.85 for EPA-CHD association. A lower risk of colorectal cancer was observed at higher levels of DPA (RR: 0.76, 95% CI: 0.59-0.98) and DHA (RR: 0.80; 95% CI: 0.65-0.99), whereas no association was noted for other outcomes. In addition, a dose-response relationship was observed between an increasing level of EPA, DPA, or DHA biomarker and lower risk of CVD.
Conclusions
Higher concentrations of marine-derived omega-3 PUFA biomarkers were associated with a significantly reduced risk of total CVD, CHD, and total mortality. Levels of ALA were inversely associated with a lower risk of T2D but not CVD-related outcomes. These data support the dietary recommendations advocating the role of omega-3 PUFAs in maintaining an overall lower risk of developing cardiovascular disease and premature deaths.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.